{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:53:21Z","timestamp":1792162401298,"version":"4.4.0"},"reference-count":33,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2019,4,3]]},"DOI":"10.1080\/13696998.2019.1571499","type":"journal-article","created":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T17:01:03Z","timestamp":1547744463000},"page":"359-364","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Lacosamide as a first-line treatment option in focal epilepsy: a cost-utility analysis for the Greek healthcare system"],"prefix":"10.1080","volume":"22","author":[{"given":"Mary","family":"Geitona","sequence":"first","affiliation":[{"name":"School of Social & Political Sciences, Department of Social & Educational Policy, University of Peloponnese, Corinth, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugena","family":"Stamuli","sequence":"additional","affiliation":[{"name":"Research Fellow Department of Health Sciences, University of York, York, UK;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stylianos","family":"Giannakodimos","sequence":"additional","affiliation":[{"name":"\u2018G. Gennimatas\u2019 General Hospital of Athens, Athens, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios K.","family":"Kimiskidis","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Neurophysiology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Kountouris","sequence":"additional","affiliation":[{"name":"UCB Pharma, Athens, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mata","family":"Charokopou","sequence":"additional","affiliation":[{"name":"UCB Biopharma SPRL, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Christou","sequence":"additional","affiliation":[{"name":"UCB Pharma, Athens, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,2,8]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2010.10.027"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2005.66104.x"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02522.x"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13670"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.t01-1-26901.x"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1097\/00019052-200004000-00007"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2008.09.007"},{"key":"CIT0008","doi-asserted-by":"crossref","DOI":"10.17226\/13379","volume-title":"Quality of Life and Community Resources in Epilepsy Across the Spectrum: Promoting Health and Understanding","author":"England MJ","year":"2012"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1186\/1744-859X-6-28"},{"issue":"12","key":"CIT0010","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/j.1528-1167.2007.01251.x","volume":"48","author":"Pugliatti M","year":"2007","journal-title":"Epilepsia"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70301-0"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199503030-00005"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2764"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)30292-7"},{"key":"CIT0015","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders. EMA, London, UK; 2010 [cited 2017 July 13]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/01\/WC500070043.pdf."},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12074"},{"key":"CIT0017","unstructured":"Hellenic Neurological Society. Guidelines on the pharmacological treatment of epilepsy \u2013 updated. HNS, Athens, Greece; 2015. [Date accessed: November 2018] Available from: http:\/\/www.enee.gr\/el\/therapeftika-protokolla-ene\/161-2015"},{"key":"CIT0018","unstructured":"Greek Ministry of Health. Positive Reimbursement List. Governmental Gazette 479b, February 17, 2017."},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.09.111"},{"key":"CIT0020","unstructured":"National Institute for Health and Clinical Excellence. The guidelines manual. NICE, London, UK; 2012. [Date accessed: January 2017] Available from: www.nice.org.uk."},{"key":"CIT0021","unstructured":"Hellenic Statistical Authority. Athens, Greece. Population Census 2011. Permanent population by sex, age group and place of birth (region, country of origin). Total in country and regions. Table A01. http:\/\/www.statistics.gr\/el\/statistics\/-\/publication\/SAM03\/-"},{"key":"CIT0022","unstructured":"Hellenic Statistical Authority. Athens, Greece Deaths in Greece by sex, age and cause (2000-2015) http:\/\/www.statistics.gr\/el\/statistics\/-\/publication\/SPO09\/-%A0%BD%B1%BA%B1%C2%20A1605_SPO09_TS_AN_00_2000_00_2015_02_F_GR."},{"key":"CIT0023","unstructured":"Baulac M, Rosenow F, Toledo M, et al. Location of congress: Copenhagen, Denmark. Date of congress: May 28\u201331, 2016."},{"key":"CIT0024","unstructured":"UCB. Data on File (SP0993 Final Tables. Table 2.2.1.). 2015."},{"key":"CIT0025","unstructured":"IMS Greece. MIDAS data. National Audit. Update December 2016."},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01164.x"},{"key":"CIT0027","unstructured":"Mulhern B, Brazier J, Hughes D, et\u00a0al. Psychometric analysis of health state utility measures in epilepsy. Unpublished. 2015."},{"key":"CIT0028","unstructured":"GlaxoSmithKline. Retigabine as an adjunctive treatment for partial onset seizures with or without secondary generalisation in adults aged 18 years and above with epilepsy - Specification for manufacturer\/sponsor submission of evidence. National Institute For Health And Clinical Excellence, London, UK; 2011; Single Technology Appraisal (STA)."},{"key":"CIT0029","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"Briggs A","year":"2006"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318271f77e"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01794.x"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2013.09.046"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.08.896"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2019.1571499","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T05:20:56Z","timestamp":1720934456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2019.1571499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,8]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4,3]]}},"alternative-id":["10.1080\/13696998.2019.1571499"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2019.1571499","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-10-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}